Non-Melanoma Skin Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Non-Melanoma Skin Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global non-melanoma skin cancer treatment market size reached US$ 535.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 725.7 Million by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2022-2028.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient’s body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on treatment type, indication and end use.

Breakup by Treatment Type:

Chemotherapy

Radiation Therapy

Photodynamic Therapy

Others



Breakup by Indication:

Basal Cell Carcinoma

T-Cell Lymphoma

Squamous Cell Carcinoma

Others



Breakup by End Use:

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Others



Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa



Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.

Key Questions Answered in This Report:

How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?

What are the key regional markets?

What is the breakup of the market based on the treatment type?

What is the breakup of the market based on the indication?

What is the breakup of the market based on the end use?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?

What is the degree of competition in the industry?